A ribosomal protein is hiding inside liver cancer's immune shield — CRISPR found it
CRISPR started as a cut-and-paste tool for DNA. It has quietly become one of the most versatile instruments in biology — screening thousands of genes at once, detecting pathogens in under an hour, and now rewriting single letters of the genome with surgical precision.
This week's papers show how wide that toolkit has stretched.
🎯 An In Vivo CRISPR Screen Fingers a Ribosomal Protein as Liver Cancer's Immune Escape Artist
- Researchers ran a CRISPR knockout screen across 4,500 genes in live mouse models of hepatocellular carcinoma (HCC) — one of the harder cancers to treat with immunotherapy — and a ribosomal protein called RPS19 kept surfacing as a key enabler of immune evasion.
- Deleting RPS19 in tumor cells remodeled the surrounding immune environment. Single-cell RNA sequencing traced the mechanism to tumor-associated macrophages, which receive RPS19 signals through a receptor called C5aR1 and then suppress immune activity.
- The team built nanoparticles modified with a tumor-homing peptide to deliver CRISPR-Cas9 directly to HCC cells. The particles released their payload inside the glutathione-rich tumor environment, knocked down RPS19, and suppressed tumor progression in vivo.
Why it matters: Most immunotherapy research chases the usual suspects — checkpoint proteins, T cells. Finding a ribosomal protein at the center of macrophage-driven immune suppression opens a different angle on why HCC resists treatment.
Key Findings
⚙️ A Dual Base Editor That Changes One Letter — and Almost Nothing Else
- Engineers shortened the linker connecting the Cas12m protein to its deaminase domain and produced a dual base editor capable of both A-to-G and C-to-T substitutions at a single target nucleotide.
- The result: up to 90% editing efficiency with bystander edits below 0.8% — a meaningful precision gain over earlier broad-window editors that routinely alter neighboring bases.
🍇 Gene-Edited Grapevines Resist Powdery Mildew — With One Catch
- CRISPR knockouts across four MLO genes in grapevine revealed a hierarchy: MLO17 contributes most to powdery mildew susceptibility, followed by MLO3 and MLO13, with MLO4 playing a smaller but consistent modifier role.
- Fully knocking out all four genes produced resistance but also triggered developmental defects in flowers. Vines with partial chimerism — some wild-type MLO4 alleles remaining — achieved resistance without the growth penalties.
🧫 A Meta-Analysis of HIV CRISPR Screens Surfaces Unexpected Pathways
- Pooling results from 11 genome-wide CRISPR-Cas9 screens across 26 gene lists, researchers confirmed known HIV dependency factors like CD4 and LEDGF/p75, and flagged RNF114 as the top-ranked restriction factor across four independent study categories.
- Less expected: coagulation and IL-17 signaling appeared among dependency factors, and the Integrator complex showed up in latency-promoting genes — neither pathway is a canonical target in HIV biology.
💉 A PEG Replacement for Lipid Nanoparticles Cuts Toxicity 12-Fold in Cell Tests
- A polymer called PEtOx, attached to a cholesterol anchor, was tested as a stealth coating for lipid nanoparticles instead of the standard PEG. In cell experiments, PEtOx versions showed 12-fold lower cytotoxicity and a 99% reduction in red blood cell damage compared to PEG analogues.
- The formulation was manufactured without organic solvents and successfully delivered mRNA in vitro; in vivo, 66.5% of macrophages took up PEtOx nanoparticles.
🔬 Eight-Pathogen Lung Infection Panel Reads Out in Two Hours Using CRISPR Droplets
- A multiplexed droplet platform paired combinatorial fluorescence color-coding with CRISPR-Cas12a detection to simultaneously quantify eight bacterial pathogens linked to lower respiratory tract infections.
- Validated on 30 clinical lung fluid samples, the assay matched standard culture results with 100% positive agreement and 99.1% negative agreement — and the full workflow runs in about two hours.
🧬 A Transcription Factor Flips IL-13 On and IL-4 Off in Immune Cells
- A CRISPR screen targeting 2,394 mouse transcription factors in Th2 immune cells identified Cbfβ as a factor that simultaneously boosts IL-13 production and suppresses IL-4 — two cytokines that usually travel together in allergic responses.
- Mechanistically, Cbfβ binds the IL-13 promoter through a Cbfβ/Runx complex and promotes DNA looping between the promoter and distant enhancers, independently of GATA3, the canonical Th2 master regulator.
Implications
CRISPR's diagnostic and therapeutic arms are converging fast — the same logic powering cancer screens is now running in droplets to catch lung infections in two hours. The open question: whether precision tools like single-nucleotide base editors and tumor-targeted nanoparticles can survive the translation from mouse models to the messier biology of human patients.
Studies in this issue
Primary sources used for this newsletter.
- Using CRISPR in living models to identify RPS19 as a target for immunotherapy in liver cancermain storyAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-10-26PMID 42928503
- Rapid Test Using Fluorescent DNA Amplification and CRISPR to Detect Bacteria in Lower Lung Infectionskey findingACS nano2026-10-27PMID 42937587
- High-Precision Virus-Like Particles Carrying Cas12m for Changing DNA Bases from A to G and C to Tkey findingGenes2026-10-27PMID 42938363
- Gene Editing of Grapevine MLO Genes Linked to Powdery Mildew Resistance and Plant Growthkey findingPlants (Basel, Switzerland)2026-10-27PMID 42943120
- Combined Analysis of Genetic Screens to Find Human Factors Involved in HIV-1 Infectionkey findingViruses2026-10-27PMID 42944055
- Comparing Two Polymers for Making Lipid Nanoparticles Without Organic Solventskey findingAngewandte Chemie (International ed. in English)2026-10-27PMID 42935313
- Cbfβ controls DNA folding to regulate different Il4 and Il13 gene activity in Th2 immune cellskey findingThe Journal of experimental medicine2026-10-28PMID 42949637
Continue reading
All CRISPR Gene Editing issuesGet the next CRISPR Gene Editing issue
Seven papers, once a week. Free.